Valued at a market cap of $23.7 billion, Moderna, Inc. (MRNA) is a biotechnology company focused on developing messenger RNA (mRNA)-based medicines and vaccines. Headquartered in Cambridge, Massachusetts, Moderna aims to use mRNA technology to instruct the body's cells to produce proteins that can prevent or treat diseases.
The biotech titan is expected to announce its fiscal Q2 earnings for 2026 before the market opens on Friday, Jul. 31. Ahead of this event, analysts expect this biotechnology company to report a loss of $1.97 per share, an improvement of 7.5% from a loss of $2.13 per share in the year-ago quarter. The company has topped Wall Street’s bottom-line estimates in each of the last four quarters.